MenACWY-TT vaccine for active immunization against invasive meningococcal disease

Expert Review of Vaccines

Volumn 11, Issue 5, 2012, Pages 523-537

  Papaevangelou, Vassiliki ^a   Spyridis, Nikos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

antibody persistence; bacterial meningitis; concomitant vaccination; immune memory; immunogenicity; Neisseria meningitidis serogroups; quadrivalent meningococcal conjugate vaccine; reactogenicity

Indexed keywords

CARRIER PROTEIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; HEPATITIS A HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENAFRICVAX; MENINGOCOCCUS VACCINE; POLYSACCHARIDE; POLYSACCHARIDE VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; AFRICA; AGE DISTRIBUTION; ANTIBODY TITER; COMPARATIVE STUDY; DEVELOPED COUNTRY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ENDEMIC DISEASE; EPIDEMIC; HEADACHE; HERD IMMUNITY; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREGULATION; INCIDENCE; INDUSTRIALIZATION; INFECTION PREVENTION; INFECTION SENSITIVITY; INJECTION SITE ERYTHEMA; INJECTION SITE IRRITATION; MASS IMMUNIZATION; MEMORY CELL; MENINGOCOCCOSIS; MORBIDITY; MORTALITY; NEISSERIA MENINGITIDIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK FACTOR; URTICARIA;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; HUMANS; INCIDENCE; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETANUS TOXOID; TREATMENT OUTCOME; VACCINATION; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84862550254     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.32     Document Type: Review

References (102)

1. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N. Engl. J. Med. 344(18), 1378-1388 (2001
2. Tan LK, Carlone GM, Borrow R. AdVances in the development of vaccines against Neisseria meningitidis. N. Engl. J. Med. 362(16), 1511-1520 (2010
3. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 27(Suppl. 2), B51-B63 (2009
4. Gardner P. Clinical practice. Prevention of meningococcal disease. N. Engl. J. Med. 355(14), 1466-1473 (2006
5. Caugant DA, Tzanakaki G, Kriz P. Lessons from meningococcal carriage studies. FEMS Microbiol. Rev. 31(1), 52-63 (2007
6. Greenwood B. Editorial: 100 years of epidemic meningitis in West Africa - has anything changed? Trop. Med. Int. Health 11(6), 773-780 (2006
7. Fellick JM, Sills JA, Marzouk O, Hart CA, Cooke RW, Thomson AP. Neurodevelopmental outcome in meningococcal disease: a case-control study. Arch. Dis. Child. 85(1), 6-11 (2001
8. Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin. Infect. Dis. 33(5), 737-739 (2001
9. Kaplan SL, Schutze GE, Leake JA et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 118(4), e979-e984 (2006
10. Poland GA. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clin. Infect. Dis. 50(Suppl. 2), S45-S53 (2010
11. Maiden MC, Ibarz-Pavón AB, Urwin R et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis. 197(5), 737-743 (2008
12. Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R; Canadian Immunization Monitoring Program, Active (IMPACT). The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr. Infect. Dis. J. 28(3), 220-224 (2009
13. Simpkins D, Wood N, Jelfs J et al. Modern trends in mortality from meningococcal disease in Australia. Pediatr. Infect. Dis. J. 28(12), 1119-1120 (2009
14. Macneil JR, Cohn AC, Zell ER et al.; Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr. Infect. Dis. J. 30(6), 451-455 (2011
15. Harrison LH, Pelton SI, Wilder-Smith A et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 29(18), 3363-3371 (2011
16. Epidemics of meningococcal disease. African meningitis belt, 2001. Wkly Epidemiol. Rec. 76(37), 282-288 (2001
17. Greenwood BM, Bradley AK, Cleland PG et al. An epidemic of meningococcal infection at Zaria, Northern Nigeria. 1. General epidemiological features. Trans. R Soc. Trop. Med. Hyg. 73(5), 557-562 (1979
18. Irving TJ, Blyuss KB, Colijn C, Trotter CL. Modelling meningococcal meningitis in the African meningitis belt. Epidemiol. Infect. 1-9 (2011
19. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005. Can. Commun. Dis. Rep. 33(10), 1-15 (2007
20. Harrison LH, Kreiner CJ, Shutt KA et al.; Meningococcal High School Study Group. Risk factors for meningococcal disease in students in grades 9-12. Pediatr. Infect. Dis. J. 27(3), 193-199 (2008
21. MacLennan J, Kafatos G, Neal K et al.; United Kingdom Meningococcal Carriage Group. Social behavior and meningococcal carriage in British teenagers. Emerging Infect. Dis. 12(6), 950-957 (2006
22. Olyhoek T, Crowe BA, Achtman M. Clonal population structure of Neisseria meningitidis serogroup A isolated from epidemics and pandemics between 1915 and 1983. Rev. Infect. Dis. 9(4), 665-692 (1987
23. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin. Microbiol. Rev. 19(1), 142-164 (2006
24. Vogel U, Claus H, Frosch M. Rapid serogroup switching in Neisseria meningitidis. N. Engl. J. Med. 342(3), 219-220 (2000
25. Linz B, Schenker M, Zhu P, Achtman M. Frequent interspecific genetic exchange between commensal Neisseriae and Neisseria meningitidis. Mol. Microbiol. 36(5), 1049-1058 (2000
26. Mölling P, Bäckman A, Olcén P, Fredlund H. Comparison of serogroup W-135 meningococci isolated in Sweden during a 23-year period and those associated with a recent hajj pilgrimage. J. Clin. Microbiol. 39(7), 2695-2699 (2001
27. Mayer LW, Reeves MW, Al-Hamdan N et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electrophoretic type-37 complex. J. Infect. Dis. 185(11), 1596-1605 (2002
28. Borrow R, Findlow J. Prevention of meningococcal serogroup C disease by NeisVac-C. Expert Rev. Vaccines 8(3), 265-279 (2009
29. Ibarz-Pavón AB, Maclennan J, Andrews NJ et al. Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation. J. Infect. Dis. 204(7), 1046-1053 (2011
30. Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357(9251), 195-196 (2001
31. Boisier P, Nicolas P, Djibo S et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin. Infect. Dis. 44(5), 657-663 (2007
32. Achtman M. Global epidemiology of meningococcal disease. In: Meningococcal Disease. Cartwright K (Ed.). Wiley, NY, USA, 159-176 (1995
33. Coulson GB, von Gottberg A, du Plessis M, Smith AM, de Gouveia L, Klugman KP; Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa. Meningococcal disease in South Africa, 1999-2002. Emerging Infect. Dis. 13(2), 273-281 (2007
34. Tapsall J; Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2007. Commun. Dis. Intell. 32(3), 299-307 (2008
35. O'Hallahan J, Lennon D, Oster P et al. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine 23(17-18), 2197-2201 (2005
36. Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int. J. Epidemiol. 38(2), 413-418 (2009
37. Holst J, Martin D, Arnold R et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27(Suppl. 2), B3-B12 (2009
38. CDC. Updated recommendations for use of meningococcal conjugate vaccines - Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 60(3), 72-76 (2010
39. Law DK, Lorange M, Ringuette L et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J. Clin. Microbiol. 44(8), 2743-2749 (2006
40. Tsang RS, Squires SG, Zollinger WD, Ashton FE. Distribution of serogroups of Neisseria meningitidis and antigenic characterization of serogroup Y meningococci in Canada, January 1, 1999 to June 30, 2001. Can. J. Infect. Dis. 13(6), 391-396 (2002
41. Gabastou JM, Agudelo CI, Brandileone MC, Castañeda E, de Lemos AP, Di Fabio JL; Grupo de Laboratorio de SIREVA II. [Characterization of invasive isolates of S. pneumoniae, H. influenzae, and N. meningitidis in Latin America and the Caribbean: SIREVA II, 2000-2005]. Rev. Panam. Salud Publica 24(1), 1-15 (2008
42. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis. 10(12), 853-861 (2010
43. Claus H, Maiden MC, Wilson DJ et al. Genetic analysis of meningococci carried by children and young adults. J. Infect. Dis. 191(8), 1263-1271 (2005
44. Ala'aldeen DA, Oldfield NJ, Bidmos FA et al. Carriage of meningococci by university students, United Kingdom. Emerging Infect. Dis. 17(9), 1762-1763 (2011
45. Edwards EA, Devine LF, Sengbusch GH, Ward HW. Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. Scand. J. Infect. Dis. 9(2), 105-110 (1977
46. De Wals P, Gilquin C, De Maeyer S. [Methods for analyzing the frequency, prevalence and the duration of asymptomatic carriage of Neisseria meningitidis. Longitudinal study of a school population in Belgium]. Med. Trop. (Mars) 42(5), 537-543 (1982
47. Trotter CL, Greenwood BM. Meningococcal carriage in the African meningitis belt. Lancet Infect. Dis. 7(12), 797-803 (2007
48. Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol. Infect. 134(3), 556-566 (2006
49. Cooper B, DeTora L, Stoddard J. Menveo®: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev. Vaccines 10(1), 21-33 (2011
50. Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin. Infect. Dis. 50(Suppl. 2), S37-S44 (2010
51. Honish L, Soskolne CL, SenthilselVan A, Houston S. Modifiable risk factors for invasive meningococcal disease during an Edmonton, Alberta outbreak, 1999-2002. Can. J. Public Health. 99(1), 46-51 (2008
52. Emonts M, Hazelzet JA, de Groot R, Hermans PW. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect. Dis. 3(9), 565-577 (2003
53. Imrey PB, Jackson LA, Ludwinski PH et al. Meningococcal carriage, alcohol consumption, and campus bar patronage in a serogroup C meningococcal disease outbreak. J. Clin. Microbiol. 33(12), 3133-3137 (1995
54. Fischer M, Hedberg K, Cardosi P et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr. Infect. Dis. J. 16(10), 979-983 (1997
55. Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA 286(6), 688-693 (2001
56. Kriz P, Bobak M, Kriz B. Parental smoking, socioeconomic factors, and risk of invasive meningococcal disease in children: a population based case-control study. Arch. Dis. Child. 83(2), 117-121 (2000
57. Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 27(Suppl. 2), B20-B29 (2009
58. Cano R, Larrauri A, Mateo S, Alcalá B, Salcedo C, Vázquez JA. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill. 9(7), 11-15 (2004
59. Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol. Rev. 31(1), 101-107 (2007
60. Booy R, Jelfs J, El Bashir H, Nissen MD. Impact of meningococcal C conjugate vaccine use in Australia. Med. J. Aust. 186(3), 108-109 (2007
61. de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, Van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in The Netherlands. Pediatr. Infect. Dis. J. 25(1), 79-80 (2006
62. Maiden MC, Stuart JM; UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359(9320), 1829-1831 (2002
63. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin. Vaccine Immunol. 17(5), 840-847 (2010
64. Kinlin LM, Jamieson F, Brown EM et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. Vaccine 27(11), 1735-1740 (2009
65. Trotter CL, Borrow R, Findlow J et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin. Vaccine Immunol. 15(11), 1694-1698 (2008
66. LaForce FM, Konde K, Viviani S, Préziosi MP. The Meningitis Vaccine Project. Vaccine 25(Suppl. 1), A97-100 (2007
67. Bilukha OO, Rosenstein N; National Center for Infectious Diseases, CDC. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recomm. Rep. 54(RR-7), 1-21 (2005
68. Snape MD, Kelly DF, Salt P et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin. Infect. Dis. 43(11), 1387-1394 (2006
69. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9(3), 213-220 (2009
70. Ortega-Sanchez IR, Meltzer MI, Shepard C et al.; Active Bacterial Core Surveillance Team. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin. Infect. Dis. 46(1), 1-13 (2008
71. Patel MS. Australia's century of meningococcal disease: development and the changing ecology of an accidental pathogen. Med. J. Aust. 186(3), 136-141 (2007
72. CDC. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. Morbid. Mortal. Wkly Rep. 60, 1391-1392 (2011
73. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type B conjugate vaccines. Immunology 113(2), 163-174 (2004
74. Diez-Domingo J, Cantarino MV, Torrenti JM et al.; MenC Study Group. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr. Infect. Dis. J. 29(2), 148-152 (2010
75. Knuf M, Kieninger-Baum D, Habermehl P et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 28(3), 744-753 (2010
76. Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 27(1), 161-168 (2009
77. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 27(Suppl. 2), B112-B116 (2009
78. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 23(17-18), 2222-2227 (2005
79. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol. 10(5), 780-786 (2003
80. Pace D. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy. Expert Rev. Vaccines 8(5), 529-542 (2009
81. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev. Vaccines 8(7), 851-861 (2009
82. Klein NP, Medford S, Malacaman E et al. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy toddlers. Presented at: 48th Annual Meeting Infectious Disease Society of America. BC, Canada, 21-24 October 2010.
83. Vesikari T, Karvonen A, Lindblad N, Poolman J, Boutriau D. Immunogenicity of one dose of an investigational meningococcal tetravalent tetanus-toxoid conjugate (ACWY-TT) vaccine in 1-2 year-olds. Presented at: 27th Annual meeting of the European Society for Pediatric Infectious Diseases. Brussels, Belgium, 9-13 June 2009.
84. Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when coadministered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial. Vaccine 29(25), 4274-4284 (2011
85. Vesikari T, Karvonen A, Korhonen T, Poolman J, Boutriau D. Immunogenicity of one dose of an investigational meningococcal tetravalent tetanus-toxoid conjugate (ACWY-TT) vaccine in 2-10 year-olds. Presented at: 27th Annual meeting of the European Society for Pediatric Infectious Diseases. Brussels, Belgium, 9-13 June 2009.
86. Knuf M, Romain O, Krause K-H et al. The candidate MENACWY-TT conjugate vaccine is immunogenic and has an acceptable safety profile in children 2-10 years of age. Presented at: 28th Annual meeting of the European Society for Pediatric Infectious Diseases. Nice, France, 4-8 May 2010.
87. Memish ZA, Dbaibo G, Montellano M et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed- ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr. Infect. Dis. J. 30(4), e56-e62 (2011
88. Bermal N, Huang LM, Dubey AP et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum. Vaccin. 7(2), 239-247 (2011
89. Borja-Tabora CM, Memish Z, Gatchalian S, Boutriau D, Van der Wielen M, Miller J. Immunogenicity of one dose of an investigational meningococcal tetravalent tetanus-toxoid conjugate (MENACWYTT) vaccine in 11-17 years old. Presented at: 6th World Society of Pediatric Infectious Diseases. Buenos Aires, Argentina, 19-22 November 2009.
90. Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr. Infect. Dis. J. 30(3), e41-e48 (2011
91. Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine 28(3), 657-663 (2010
92. Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr. Infect. Dis. J. 28(2), 86-91 (2009
93. Perrett KP, Snape MD, Ford KJ et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr. Infect. Dis. J. 28(3), 186-193 (2009
94. Halperin SA, Gupta A, Jeanfreau R et al. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Vaccine 28(50), 7865-7872 (2010
95. Dbaibo G, Macalalad N, Aplasca-De Los Reyes MR et al. The immunogenicity of the candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (MENACWY-TT) is non-inferior to the licensed meningococcal tetravalent polysaccharide vaccine and has an acceptable safety profile in adults. Presented at: 3rd Northern European Conference on Travel Medicine. Hamburg, Germany, 26-29 May 2010.
96. Macalalad N, Aplasca-De Los Reyes MR, Dimaano E et al. The candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (MENACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when coadministered in adults. Presented at: 3rd Northern European Conference on Travel Medicine. Hamburg, Germany, 26-29 May 2010.
97. Vesikari T, Karvonen A, Lindblad N et al. Immunogenicity of one dose of an investigational meningococcal tetravalent tetanus-toxoid conjugate (MENACWY-TT) vaccine in toddlers and children one year after vaccination. Presented at: 6th World Society of Pediatric Infectious Diseases. Buenos Aires, Argentina, 19-22 November 2009.
98. Knuf M, Prieler A, Poolman J, Vink P, Boutriau D. Antibody persistence and immune memory 15 months after meningococcal tetravalent tetanus-toxoid conjugate (ACWY-TT) vaccine in toddlers and 3-5 year-olds. Presented at: 27th Annual meeting of the European Society for Pediatric Infectious Diseases. Brussels, Belgium, 9-13 June 2009.
99. Østergaard L, Bianco V, Van der Wielen M, Miller J. Persistence of immune response to candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid-conjugated vaccine (MENACWY-TT) up to 42 months following primary vaccination. Presented at: 3rd Congress of the European Academy of Paediatric Societies. Copenhagen, Denmark, 23-26 October 2010.
100. Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine coadministered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine 29(25), 4264-4273 (2011
101. Vesikari T, Bianco V, Van der Wielen M, Miller J. Immunogenicity and Safety of the coadministration of the MenACWY-TT conjugate vaccine with MMRV in toddlers. Presented at: 28th Annual meeting of the European Society for Pediatric Infectious Diseases. Nice, France, 4-8 May 2010.
102. Ostergaard L, SilfverdalSA, Schade Larsen C et al. The candidate meningococcal serogroup A, C, W-135, Y conjugate vaccine (MENACWY-TT) coadministered with a combined hepatitis A and B vaccine (HEPPA/B) is immunogenic and well tolerated in subjects aged 11-17 years. Presented at: 3rd Northern European Conference on Travel Medicine. Hamburg, Germany, 26-29 May 2010.